GlassScriptPhysician profile
Preethi Ilangovan
NPI 1992048185
$5,346.29
in general payments reported to CMS, 2019-2025
33 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.87 · 2020: $49.42 · 2021: $103 · 2022: $141 · 2023: $1,472 · 2024: $1,687 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,808 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,808.49 |
| Education | $158.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $951.47 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $748.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $474.54 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $471.87 | 2021-2025 | Evenity, Tepezza, Prolia |
| Tandem Diabetes Care, INC. | $332.69 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $235.25 | 2022-2025 | |
| Insulet Corporation | $210.43 | 2023-2025 | Omnipod |
| Medtronic, INC. | $182.45 | 2021-2025 | Minimed 780g, Minimed 770g |
| Beta Bionics, INC. | $177.55 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $177.45 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $155.66 | 2024-2025 | |
| Antares Pharma, INC. | $140.93 | 2025 | Xyosted |
| Cequr Corporation | $108.25 | 2023-2024 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $107.21 | 2023-2025 | |
| Dexcom, INC. | $101.94 | 2023-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $99.32 | 2024-2025 | Gvoke Hypopen |
| Vivus LLC | $97.14 | 2023 | Qsymia |
| Abbvie INC. | $91.94 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.55 | 2024-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $53.51 | 2021-2025 | Signifor Lar |
| Rhythm Pharmaceuticals, INC. | $50.33 | 2024-2025 | Imcivree |
| Novartis Pharmaceuticals Corporation | $45.25 | 2025 | |
| Alexion Pharmaceuticals, INC. | $43.16 | 2019-2025 | Strensiq |
| Corcept Therapeutics | $38.34 | 2025 | Korlym |
| Kyowa Kirin, INC. | $25.95 | 2025 | |
| Ascendis Pharma Endocrinology INC | $25.24 | 2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $23.59 | 2019 | |
| Radius Health, INC. | $22.25 | 2024 | Tymlos |
| Ultragenyx Pharmaceutical INC. | $20.42 | 2021 | |
| Alvogen INC | $20.39 | 2025 | Teriparatide |
| Acella Pharmaceuticals, LLC | $19.47 | 2025 | NP Thyroid 60 |
| Chiesi USA, INC. | $17.62 | 2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Ilangovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.